Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

Novo Nordisk shares fell sharply after the Danish drugmaker said a pill with semaglutide, the key ingredient in its Ozempic and Wegovy blockbuster drugs for obesity and diabetes, didn't slow Alzheimer ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen ...